title: 4-Hydroxy-oxyphenbutazone is a potent inhibitor of cytokine production.
abstract: 4-Hydroxy-oxyphenbutazone (4OH-OPB), is currently in phase II trials for its immunosuppressive effect in patients with rheumatoid arthritis. 4OH-OPB and other compounds related to phenylbutazone were tested for their effect on in vitro cytokine production by monocytes and lymphocytes present in peripheral mononuclear cells (PBMC) or whole blood (WB) cultures, and compared against phenylbutazone and oxyphenbutazone, two known anti-inflammatory drugs. In PBMC cultures, 4OH-OPB was by far the most potent inhibitor, and both monokines and Th1 and Th2 lymphokines were efficiently inhibited at low concentrations. In WB cultures, 4OH-OPB was less effective than in PBMC cultures, but was still the best inhibitor of lymphokine production and, furthermore, was the only inhibitor of monokine production. The increase in 4OH-OPB concentration needed to induce the same inhibition of cytokine production in WB as in PBMC culture could be mimicked by the addition of erythrocytes to the PBMC cultures. Experiments with radioactively-labeled 4OH-OPB suggest that 4OH-OPB is taken up very rapidly into erythrocytes and is secreted by the erythrocytes with much slower kinetics via a multidrug-resistance-associated protein. The secreted compound is most likely structurally different from 4OH-OPB, as in PBMC and WB cultures, the inhibition of cytokine production seems to be caused by a different mechanism. In PBMC cultures, the inhibition of cytokine production is accompanied by a loss of cell viability, while this is not the case when 4OH-OPB inhibits cytokine production in WB. Our data suggest that 4OH-OPB may be useful as an immunosuppressive drug for patients with inflammatory diseases.
authors.affiliation: Department of Immunopathology, Sanquin Research at CLB, PO.BOX 9190, 1006 AD Amsterdam, The Netherlands. a.tenbrinke@sanquin.nl
authors.forename: Anja
authors.initials: A
authors.lastname: Ten Brinke
authors.forename: David W C
authors.initials: DW
authors.lastname: Dekkers
authors.forename: Silla M
authors.initials: SM
authors.lastname: Notten
authors.forename: Miriam L
authors.initials: ML
authors.lastname: Karsten
authors.forename: Els R
authors.initials: ER
authors.lastname: de Groot
authors.forename: Lucien A
authors.initials: LA
authors.lastname: Aarden
mesh_terms: D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000096:biosynthesis; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D010113:Oxyphenbutazone / Q000031:analogs & derivatives* / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D000093242:Interleukin-6 Inhibitors
chemical_list: D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015850:Interleukin-6; D010113:Oxyphenbutazone; D000093242:Interleukin-6 Inhibitors; C505429:4-hydroxy-oxyphenbutazone